InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.77%
)
US TECH 100
19,386.80
(
1.14%
)
Dow Jones
38,778.10
(
0.49%
)
Brent Oil
83.90
(
2.16%
)
Bitcoin
66,476.67
(
-0.24%
)
Post# of 252227
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: None

Saturday, 11/02/2013 10:09:02 AM

Saturday, November 02, 2013 10:09:02 AM

Post# of 252227

Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients







http://finance.yahoo.com/news/gilead-announces-sustained-viral-response-130100600.html




The data speaks for itself. I see no reason why 24-weeks of dosing wouldn't be acceptable with these SVR rates. My apologies to the folks at GILD and good luck on the launch.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up